Skip to content

Study · Not a test of the peptide alone · 2002

5 results

Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig.

Igarashi H, Ito T, Hou W, Mantey SA, Pradhan TK, Ulrich CD 2nd, Hocart SJ, Coy DH, Jensen RT

The Journal of pharmacology and experimental therapeutics1 Apr 2002Cited by 33 (Europe PMC)

PMID11907155 (opens in a new tab)DOI10.1124/jpet.301.1.37 (opens in a new tab)PepBankPUB-11907155
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In cell assays with alanine and D-amino acid scanning, the VIP pharmacophore for VPAC(1) differed between species.

    In plain wordsIn lab tests, the parts of VIP that matter for binding to its receptor differed between species.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSpecies differences in the VIP pharmacophore for VPAC(1)
    Study

    human, rat, guinea pign: not reported in source

    CHO and PANC1 cells with VPAC(1); T47D cells with native VPAC(1)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Important species differences existed in the VIP pharmacophore.
    2 context sentences
    Summary · context
    To address this issue we investigated the VIP pharmacophore for VPAC(1) (the predominant receptor subtype in cancers and widely distributed in normal tissues) by using alanine and D-amino acid scanning.
    Summary · context
    Interaction with rat, guinea pig, and human VPAC(1) was assessed using transfected Chinese hamster ovary (CHO) and PANC1 cells and cells possessing native VPAC(1).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, human VPAC(1) expressed in CHO cells differed markedly from native VPAC(1) in T47D cells.

    In plain wordsIn lab tests, the human receptor made in CHO cells behaved very differently from the natural receptor in T47D cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableHuman VPAC(1) in CHO cells versus native VPAC(1) in T47D cells
    Study

    human, rat, guinea pign: not reported in source

    CHO and PANC1 cells with VPAC(1); T47D cells with native VPAC(1)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The human VPAC(1) expressed in CHO cells, which were used almost exclusively in previous studies, differed markedly from the native VPAC(1) in T47D cells.
    2 context sentences
    Summary · context
    To address this issue we investigated the VIP pharmacophore for VPAC(1) (the predominant receptor subtype in cancers and widely distributed in normal tissues) by using alanine and D-amino acid scanning.
    Summary · context
    Interaction with rat, guinea pig, and human VPAC(1) was assessed using transfected Chinese hamster ovary (CHO) and PANC1 cells and cells possessing native VPAC(1).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, His(1), Asp(3), Phe(6), Arg(12), Arg(14) and Leu(23) were the most important residues for affinity at VPAC(1).

    In plain wordsIn lab tests, six named amino acids of VIP were the most important for how tightly it binds the VPAC(1) receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableResidues most important for VIP affinity at VPAC(1)
    Study

    human, rat, guinea pign: not reported in source

    CHO and PANC1 cells with VPAC(1); T47D cells with native VPAC(1)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The most important amino acids for determining affinity are His(1), Asp(3), Phe(6), Arg(12), Arg(14), and Leu(23).
    2 context sentences
    Summary · context
    To address this issue we investigated the VIP pharmacophore for VPAC(1) (the predominant receptor subtype in cancers and widely distributed in normal tissues) by using alanine and D-amino acid scanning.
    Summary · context
    Interaction with rat, guinea pig, and human VPAC(1) was assessed using transfected Chinese hamster ovary (CHO) and PANC1 cells and cells possessing native VPAC(1).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, Ser(2), Asp(8), Asn(9), Thr(11), Val(19), Asn(24), Ser(25), Leu(27) and Asn(28) were not essential for high-affinity interaction or activation of VPAC(1).

    In plain wordsIn lab tests, nine named amino acids of VIP were not needed for tight binding to the VPAC(1) receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableResidues not essential for VIP activity at VPAC(1)
    Study

    human, rat, guinea pign: not reported in source

    CHO and PANC1 cells with VPAC(1); T47D cells with native VPAC(1)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Ser(2), Asp(8), Asn(9), Thr(11), Val(19), Asn(24), Ser(25), Leu(27), and Asn(28) are not essential for high-affinity interaction/activation.
    2 context sentences
    Summary · context
    To address this issue we investigated the VIP pharmacophore for VPAC(1) (the predominant receptor subtype in cancers and widely distributed in normal tissues) by using alanine and D-amino acid scanning.
    Summary · context
    Interaction with rat, guinea pig, and human VPAC(1) was assessed using transfected Chinese hamster ovary (CHO) and PANC1 cells and cells possessing native VPAC(1).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In cell assays, the 11-alanine VIP analog [Ala(2,8,9,11,19,24,25,27,28)]VIP was equipotent to VIP at VPAC(1) receptors in all species and was metabolically stable.

    In plain wordsIn lab tests, a simplified VIP analog with 11 alanines worked as strongly as VIP at the VPAC(1) receptor in all species and was stable.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicablePotency of a simplified 11-alanine VIP analog at VPAC(1)
    Study

    human, rat, guinea pign: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    [Ala(2,8,9,11,19,24,25,27,28)]VIP, which contained 11 alanines, was synthesized and it was equipotent to VIP at VPAC(1) receptors in all species and was metabolically stable.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.